Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS

Detalles Bibliográficos
Autores principales: Novi, Giovanni, Ivaldi, Federico, Sbragia, Elvira, Mikulska, Malgorzata, Pesce, Giampaola, Inglese, Matilde, Kerlero de Rosbo, Nicole, Uccelli, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Clinical/Scientific Notes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051194/
https://www.ncbi.nlm.nih.gov/pubmed/32098867
http://dx.doi.org/10.1212/NXI.0000000000000695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051194/
https://www.ncbi.nlm.nih.gov/pubmed/32098867
http://dx.doi.org/10.1212/NXI.0000000000000695

Ejemplares similares